Belite Bio (BLTE) Competitors $56.21 +3.17 (+5.98%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends BLTE vs. LNTH, BPMC, BBIO, LEGN, ELAN, CYTK, NUVL, GRFS, VKTX, and AXSMShould you be buying Belite Bio stock or one of its competitors? The main competitors of Belite Bio include Lantheus (LNTH), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Nuvalent (NUVL), Grifols (GRFS), Viking Therapeutics (VKTX), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Belite Bio vs. Lantheus Blueprint Medicines BridgeBio Pharma Legend Biotech Elanco Animal Health Cytokinetics Nuvalent Grifols Viking Therapeutics Axsome Therapeutics Belite Bio (NASDAQ:BLTE) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, community ranking, analyst recommendations, earnings and media sentiment. Does the media favor BLTE or LNTH? In the previous week, Lantheus had 18 more articles in the media than Belite Bio. MarketBeat recorded 22 mentions for Lantheus and 4 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.14 beat Lantheus' score of 0.48 indicating that Belite Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 7 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is BLTE or LNTH more profitable? Lantheus has a net margin of 28.57% compared to Belite Bio's net margin of 0.00%. Lantheus' return on equity of 44.29% beat Belite Bio's return on equity.Company Net Margins Return on Equity Return on Assets Belite BioN/A -31.94% -30.73% Lantheus 28.57%44.29%23.52% Which has better earnings and valuation, BLTE or LNTH? Lantheus has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBelite BioN/AN/A-$31.63M-$1.11-50.64Lantheus$1.30B4.91$326.66M$6.0115.22 Which has more risk & volatility, BLTE or LNTH? Belite Bio has a beta of -1.56, meaning that its share price is 256% less volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Do analysts prefer BLTE or LNTH? Belite Bio currently has a consensus target price of $89.00, indicating a potential upside of 58.33%. Lantheus has a consensus target price of $131.86, indicating a potential upside of 44.15%. Given Belite Bio's higher possible upside, research analysts plainly believe Belite Bio is more favorable than Lantheus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Belite Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Lantheus 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in BLTE or LNTH? 0.5% of Belite Bio shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Comparatively, 2.1% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor BLTE or LNTH? Lantheus received 310 more outperform votes than Belite Bio when rated by MarketBeat users. However, 96.77% of users gave Belite Bio an outperform vote while only 65.89% of users gave Lantheus an outperform vote. CompanyUnderperformOutperformBelite BioOutperform Votes3096.77% Underperform Votes13.23%LantheusOutperform Votes34065.89% Underperform Votes17634.11% SummaryLantheus beats Belite Bio on 12 of the 16 factors compared between the two stocks. Get Belite Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLTE vs. The Competition Export to ExcelMetricBelite BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.71B$6.36B$5.24B$8.95BDividend YieldN/A2.94%5.13%4.04%P/E Ratio-50.649.7489.2317.34Price / SalesN/A315.001,255.2478.69Price / CashN/A61.4443.8235.97Price / Book17.146.055.324.79Net Income-$31.63M$154.90M$122.69M$225.00M7 Day Performance1.33%-1.71%-0.16%1.52%1 Month Performance-10.72%2.71%3.75%4.68%1 Year Performance22.60%2.79%27.40%20.89% Belite Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLTEBelite Bio3.2757 of 5 stars$56.21+6.0%$89.00+58.3%+21.8%$1.71BN/A-50.6410Short Interest ↓News CoveragePositive NewsGap DownLNTHLantheus4.5444 of 5 stars$94.65-1.3%$131.86+39.3%+65.5%$6.58B$1.50B15.75700Analyst ForecastShort Interest ↑BPMCBlueprint Medicines1.6812 of 5 stars$103.36+18.2%$122.72+18.7%+38.6%$6.57B$434.42M-48.99640Analyst ForecastInsider TradeShort Interest ↑Analyst RevisionNews CoverageHigh Trading VolumeBBIOBridgeBio Pharma4.0956 of 5 stars$33.73+16.0%$48.08+42.5%-8.5%$6.37B$217.77M-14.00400Short Interest ↑High Trading VolumeLEGNLegend Biotech2.545 of 5 stars$32.50-3.3%$80.62+148.0%-45.5%$5.94B$520.18M-34.211,800Short Interest ↓News CoverageELANElanco Animal Health4.4169 of 5 stars$11.72+2.5%$16.43+40.2%-18.8%$5.79B$4.45B29.309,800CYTKCytokinetics4.3231 of 5 stars$46.71+0.2%$83.64+79.1%-46.6%$5.51B$7.53M-8.68250Analyst ForecastNUVLNuvalent1.9838 of 5 stars$72.09-5.9%$112.36+55.9%+2.7%$5.12BN/A-20.7840Analyst ForecastInsider TradeNews CoverageGRFSGrifols3.0546 of 5 stars$7.23-0.8%N/A+7.2%$4.97B$7.01B5.9326,300Positive NewsGap DownVKTXViking Therapeutics3.9347 of 5 stars$38.88-1.1%$106.75+174.6%+52.4%$4.33BN/A-41.8120Analyst ForecastAXSMAxsome Therapeutics4.6802 of 5 stars$89.27+11.5%$129.43+45.0%+7.5%$4.33B$338.46M-13.67380Analyst Revision Related Companies and Tools Related Companies LNTH Alternatives BPMC Alternatives BBIO Alternatives LEGN Alternatives ELAN Alternatives CYTK Alternatives NUVL Alternatives GRFS Alternatives VKTX Alternatives AXSM Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BLTE) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belite Bio, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Belite Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BLTE Stock Alerts